Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18673224 | 1.00 | PARP1 (0.44) | PARP1HSD17B10SMN1; SMN2NPC1MC4R | |
| SCHEMBL654591 | 0.91 | PARP1 (0.42) | PARP1HSD17B10SMN1; SMN2NPC1MC4R | |
| SCHEMBL1634791 | 0.91 | PARP1 (0.42) | PARP1HSD17B10SMN1; SMN2NPC1MC4R | |
| SCHEMBL28442303 | 0.91 | PARP1 (0.38) | PARP1HSD17B10SMN1; SMN2NPC1MC4R | |
| SCHEMBL6350612 | 0.91 | PARP1 (0.42) | PARP1HSD17B10SMN1; SMN2NPC1MC4R | |
| Hydrochloric Acid SCHEMBL15645732 | 0.90 | PARP1 (0.42) | PARP1HSD17B10SMN1; SMN2NPC1MC4R | |
| Ammonia Solution, Strong SCHEMBL22169218 | 0.90 | PARP1 (0.42) | PARP1HSD17B10SMN1; SMN2NPC1MC4R | |
| SCHEMBL376484 | 0.88 | PARP1 (0.37) | PARP1HSD17B10MAPK1 | |
| SCHEMBL31257124 | 0.88 | PARP1 (0.37) | PARP1HSD17B10MAPK1 | |
| SCHEMBL1685922 | 0.88 | HSD17B10 (0.47) | PARP1HSD17B10SMN1; SMN2NPC1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058618-A | Antitumor cinnamyl piperazine and 2-phenylbenzimidazole conjugate, and preparation method and application thereof | 天津科技大学 | 2025-05-30 | — | — | CN | claimed |
| WO-2024134516-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | claimed |
| CN-120058618-A | Antitumor cinnamyl piperazine and 2-phenylbenzimidazole conjugate, and preparation method and application thereof | 天津科技大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-119219575-B | Antitumor cinnamyl piperazine resveratrol conjugate or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 天津科技大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-119219575-A | Antitumor cinnamyl piperazine resveratrol conjugate or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 天津科技大学 | 2024-12-31 | — | — | CN | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024134516-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| CN-117624140-A | CXCR4 antagonists, methods of making and uses thereof | 杭州师范大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-113636973-B | Industrial preparation method of 4- (6-aminopyridine-3-yl) piperazine-1-carboxylic acid tert-butyl ester | 山东铂源药业股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-113185478-B | Preparation method of N-tert-butyloxycarbonyl piperazine | 济南大学 | 2022-06-07 | — | — | CN | disclosed |
| US-5869488-A | Piperazino derivatives as neurokinin antagonists | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| US-5795894-A | TREATMENT OF ASTHMA AND BRONCHOSPASM | SCHERING CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| US-5783579-A | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists | SCHERING CORPORATION (US) | 1998-07-21 | — | — | US | disclosed |
| WO-1998028297-A1 | SPIRO-SUBSTITUTED AZACYCLIC-SUBSTITUTED PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0850236-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1998018788-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0823906-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1997008166-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996034864-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |